US Food and Drug Administration flags Sun Pharma's Halol plant, warns product approvals may be put on hold

Sun Pharmaceutical Industries seems to have suffered a setback as the US Food and Drug Administration (FDA) has placed its Halol plant under ‘official action indicated’.

FP Trending March 30, 2020 11:16:34 IST
US Food and Drug Administration flags Sun Pharma's Halol plant, warns product approvals may be put on hold

Sun Pharmaceutical Industries seems to have suffered a setback as the US Food and Drug Administration (FDA) has placed its Halol plant under ‘official action indicated’.

US Food and Drug Administration flags Sun Pharmas Halol plant warns product approvals may be put on hold

Representational image. Reuters

Informing about this to the stock exchanges on 29 March, the company said that FDA approvals for products manufactured at its plant in Gujarat’s Halol may be put on hold.

The Dilip Shanghvi-led company also faces the risk of getting a warning letter from FDA, which expects the pharma company to take corrective action at the plant.

Although Sun Pharma’s dependence on the Halol plant for its exports to the US has come down over the years, supplies to the country still contribute approximately 3 to 4 percent of its consolidated revenues.

In a letter to BSE, Sun Pharma informed that product approvals for US market may get postponed till the plant starts working in line with FDA norms. However, the current orders will be dispatched as per schedule.

The company said that it does not see any major supply disruption due to the new norm and it will work with the regulator to ensure that there will be no shortage of supply to the US.

The letter also mentioned that a re-inspection of the plant is also possible. The FDA conducted inspection of the plant in December. But, in view of the rapid spread of coronavirus , the inspection may be delayed.

 

Updated Date:

also read

Sensex surges over 300 points in early trade; HDFC, Infosys among top gainers
Business

Sensex surges over 300 points in early trade; HDFC, Infosys among top gainers

BSE index was trading 343.32 points or 0.69 percent higher at 50,005.08, and NSE Nifty advanced 102.90 points or 0.69 percent to 14,921.95

Sensex tanks over 400 points in early trade; Infosys, Tech Mahindra, TCS among gainers
Business

Sensex tanks over 400 points in early trade; Infosys, Tech Mahindra, TCS among gainers

BSE was trading 434.90 points or 0.87 percent lower at 49,594.93, and NSE Nifty dropped 109.35 points or 0.74 percent to 14,758

Six states say COVID-19 vaccine stocks petering out; Maharashtra laments getting 7.5 lakh doses as UP gets 48 lakh
India

Six states say COVID-19 vaccine stocks petering out; Maharashtra laments getting 7.5 lakh doses as UP gets 48 lakh

An analysis of available data suggests that while India is administering 34-35 lakh doses daily, its daily production capacity is no more than 26 lakh doses at present. And this is when SII is prioritising India's needs over its global obligations, as a stopgap measure